Treatment for Low Globulin (Hypoalbuminemia or Hypogammaglobulinemia)

Diagnosis and Classification

The American Academy of Allergy, Asthma, and Immunology recommends testing of immunoglobulin levels (IgG, IgA, IgM) and specific antibody responses to determine the exact deficiency in patients with low globulin levels 3
Agammaglobulinemia is characterized by very low or undetectable immunoglobulins with very low B cells, according to the Journal of Allergy and Clinical Immunology 4
Common Variable Immunodeficiency (CVID) is marked by a variable reduction in ≥2 immunoglobulin classes, as stated by the Journal of Allergy and Clinical Immunology 5
Selective IgA deficiency, IgG subclass deficiency, and specific antibody deficiency are characterized by variably low levels of specific immunoglobulin classes, as noted by the Journal of Allergy and Clinical Immunology 3
Transient hypogammaglobulinemia of infancy (THI) is marked by temporarily low immunoglobulin levels that may resolve spontaneously, according to the Journal of Allergy and Clinical Immunology 6

The National Comprehensive Cancer Network recommends intravenous immunoglobulin (IVIG) replacement therapy as the primary treatment for significantly impaired antibody production, with dosing typically at 400-500 mg/kg monthly for those with serum IgG levels <400-600 mg/dL who experience serious or recurrent infections 1, 2
IVIG/SCIG is indicated for disorders with significantly impaired antibody production, such as agammaglobulinemia, and for patients with serum IgG levels <400-600 mg/dL with serious or recurrent infections, as stated by the Journal of Allergy and Clinical Immunology 7, 2
Agammaglobulinemia requires aggressive management with IVIG and antimicrobials, according to the Journal of Allergy and Clinical Immunology 4
The American Academy of Allergy, Asthma, and Immunology recommends regular monitoring of IgG trough levels, blood cell counts, and serum chemistry every 6-12 months for patients on IVIG therapy 7
More frequent monitoring is advisable in younger growing children, as noted by the Journal of Allergy and Clinical Immunology 7
Monitor for potential adverse effects including renal dysfunction, thrombosis, and hemolysis, as stated by the Journal of Allergy and Clinical Immunology 7

The Journal of Allergy and Clinical Immunology recommends management of transient hypogammaglobulinemia of infancy (THI) to follow principles for antibody deficiency, with some patients benefiting from IgG administration, particularly during respiratory illness seasons 6
Monitor for spontaneous recovery by tracking IgG, IgA, and IgM levels, as noted by the Journal of Allergy and Clinical Immunology 6
Consider stopping IgG therapy after 3-6 months to reassess humoral immune function, according to the Journal of Allergy and Clinical Immunology 6
The National Comprehensive Cancer Network recommends monthly 400-500 mg/kg IVIG replacement for patients with serum IgG levels <400-600 mg/dL and serious or recurrent infections after CAR T-cell therapy 2
Continue IVIG until serum IgG levels normalize and infections resolve, as stated by the National Comprehensive Cancer Network 2